Description
Cvetiron 25 (Quetiapine) Coated Tablets 25 mg. №30
Composition
Active ingredient: Quetiapine fumarate 25 mg per tablet.
Mechanism of Action
Quetiapine, the active ingredient in Cvetiron 25, is an atypical antipsychotic agent that acts by modulating the effects of dopamine and serotonin in the brain. It exerts its therapeutic effects by antagonizing dopamine D2 and serotonin 5-HT2 receptors, leading to a reduction in psychotic symptoms.
Pharmacological Properties
Quetiapine demonstrates a high affinity for serotonin receptors, which contributes to its efficacy in managing schizophrenia symptoms. It also exhibits moderate affinity for noradrenergic and histaminergic receptors, adding to its pharmacological profile as an antipsychotic agent.
Indications for Use
Cvetiron 25 is indicated for the treatment of schizophrenia in adults and adolescents aged 13 years and older. It is effective in alleviating both positive and negative symptoms associated with this psychiatric disorder.
Contraindications
Avoid using Cvetiron 25 if you have a known hypersensitivity to quetiapine or any other components of the formulation. Patients with a history of quetiapine-related adverse reactions should also refrain from using this medication.
Side Effects
The use of Cvetiron 25 may lead to common side effects such as dizziness, somnolence, weight gain, and constipation. Rare but serious adverse reactions include neuroleptic malignant syndrome, tardive dyskinesia, and metabolic disturbances. Patients should be monitored closely for any signs of these side effects during treatment.
Usage Instructions
For optimal therapeutic outcomes, the recommended dosage of Cvetiron 25 is 25 mg once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water and should not be crushed, chewed, or split to maintain its controlled-release properties.
Benefits Compared to Analogues
Cvetiron 25 offers advantages over traditional antipsychotic medications by demonstrating a lower risk of extrapyramidal symptoms and a reduced likelihood of causing metabolic side effects such as weight gain and dyslipidemia. Its favorable tolerability profile makes it a preferred choice for long-term schizophrenia management.
Suitable Patient Groups
Cvetiron 25 can be safely administered to both adult and adolescent populations for the treatment of schizophrenia. However, caution should be exercised when prescribing to elderly patients due to an increased susceptibility to adverse effects like orthostatic hypotension and sedation.
Storage and Shelf Life
Store Cvetiron 25 in a cool, dry place away from direct sunlight and moisture. Ensure that the packaging is tightly closed to protect the tablets from environmental factors. Check the expiration date on the packaging and do not use the product beyond the stated shelf life.
Packaging Description
Cvetiron 25 is available in blister packs containing 30 coated tablets, each imprinted with the product name and strength for easy identification. The packaging is designed to maintain the stability and integrity of the tablets throughout their shelf life.
Clinical Evidence and Proven Effectiveness
Studies have demonstrated the efficacy of quetiapine in managing schizophrenia symptoms, including both positive and negative aspects of the disorder. Clinical trials have shown that quetiapine treatment leads to significant improvements in overall symptomatology and quality of life in patients with schizophrenia.
